Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR1 | Q08345 | 8/20 | 0.63 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | PPARD | Q03181 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.45 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.44 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13876231 | 0.83 | DDR1 (0.52) | DDR1EPHX2GAAHPGDMAPT | |
| SCHEMBL13876221 | 0.82 | EPHX2 (0.56) | DDR1MAPK14EPHX2NR1H4KCNQ3 | |
| SCHEMBL13876229 | 0.79 | EPHX2 (0.47) | DDR1MAPK14EPHX2NR1H4MAPT | |
| SCHEMBL16528098 | 0.78 | DDR1 (1.00) | DDR1MAPT | |
| SCHEMBL13876192 | 0.77 | MAPK14 (0.57) | DDR1MAPK14EPHX2PPARGPPARD | |
| SCHEMBL13876173 | 0.77 | TP53 (0.56) | DDR1MAPK14EPHX2NR1H4 | |
| SCHEMBL13876241 | 0.71 | EPHX2 (0.49) | DDR1MAPK14EPHX2NR1H4 | |
| SCHEMBL4614555 | 0.71 | MAPK14 (0.64) | MAPK14PPARGPPARDPPARA | |
| SCHEMBL4614558 | 0.71 | MAPK14 (0.64) | MAPK14PPARGPPARDPPARA | |
| SCHEMBL4615231 | 0.71 | PPARA (0.73) | MAPK14PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099184-A1 | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099184-A1 | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-16 | — | — | US | disclosed |
| WO-2007098352-A2 | SUBSTITUTED PYRIDINEAMIDE COMPOUNDS USEFUL AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099184-A1 | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors | EPHX1, EPHX2, NCEH1 | DDR1 3354/4885MAPK14 2991/4885EPHX2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.